SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2014 / Cilt: 38 - Sayı: 2

Aryl butenoic acid derivatives as a new class of histone deacetylase inhibitors: synthesis, in vitro evaluation, and molecular docking studies

Peruze AYHAN EŞİYOK
Özlem SEVEN
Gülüzar EYMUR
Gamze BORA TATAR
Didem DAYANGAÇ ERDEN
Kemal YELEKÇİ
Hayat YURTER
Ayhan Sıtkı DEMİR
Pages
338–344
Publication Date
2014-05-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These compounds have been shown to possess promising histone deacetylase inhibition activities via in vitro fluorometric assay and molecular docking studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:New aryl butenoic acid derivatives have been synthesized by combining hydroxy- or methoxy-substituted phenyl rings as the capping group, with a double bond in the short linker as well as metal binding groups, enoic ester, and salts bearing either methyl or morpholine.
📊
Key Findings & Data:New aryl butenoic acid derivatives have been synthesized by combining hydroxy- or methoxy-substituted phenyl rings as the capping group, with a double bond in the short linker as well as metal binding groups, enoic ester, and salts bearing either methyl or morpholine.
💡
Conclusion & Impact:These compounds have been shown to possess promising histone deacetylase inhibition activities via in vitro fluorometric assay and molecular docking studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Histone deacetylase inhibition activity · aryl butenoic acid derivatives · molecular docking

Abstract

New aryl butenoic acid derivatives have been synthesized by combining hydroxy- or methoxy-substituted phenyl rings as the capping group, with a double bond in the short linker as well as metal binding groups, enoic ester, and salts bearing either methyl or morpholine. These compounds have been shown to possess promising histone deacetylase inhibition activities via in vitro fluorometric assay and molecular docking studies.

Özet

New aryl butenoic acid derivatives have been synthesized by combining hydroxy- or methoxy-substituted phenyl rings as the capping group, with a double bond in the short linker as well as metal binding groups, enoic ester, and salts bearing either methyl or morpholine. These compounds have been shown to possess promising histone deacetylase inhibition activities via in vitro fluorometric assay and molecular docking studies.

🔖

Cite This Article

EŞİYOK, P. A., SEVEN, Ö., EYMUR, G., TATAR, G. B., ERDEN, D. D., YELEKÇİ, K., YURTER, H., DEMİR, A. S. (2014). Aryl butenoic acid derivatives as a new class of histone deacetylase inhibitors: synthesis, in vitro evaluation, and molecular docking studies. Turkish Journal of Chemistry, Cilt: 38 - Sayı: 2, 338–344. https://ajindex.com/articles/184679

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Ruijter, A. J. M.; Gennip, A. H.; Caron, H. N.; Kemp, S.; Kuilenburg, A. B. P. Biochem. J. 2003, 370, 737–749.
  2. Santini, V.; Gozzini, A.; Ferrari, G. Curr. Drug Metab. 2007, 8, 383–394.
  3. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Nat. Rev. Drug Disc. 2006, 5, 769–784.
  4. Liu, T.; Kuljaca, S.; Tee, A.; Marshall, G. M. Cancer Treat. Rev. 2006, 32, 157–165.
  5. Kazantsev, A. G.; Thompson, L. M. Curr. Drug Metab. 2007, 8, 383–394.
  6. Mercuri, E.; Bertini, E.; Messina, S.; Solari, A.; D’Amico, A.; Angelozzi, C.; Batini, R.; Berardinelli, A.; Boffi, P.; Bruno, C. et al. Neurology 2007, 68, 51–55.
  7. Brichta, L.; Holker, I.; Haug, K.; Klockgether, T.; Wirth, B. Ann. Neurol. 2006, 59, 970–975.
  8. Weihl, C. C.; Connolly, A. M.; Pestronk, A. Neurology 2006, 67, 500–501.
  9. Raine, C. S. J. Neuropathol. Exp. Neurol. 1994, 53, 328–337.
  10. McFarland, H. F.; Martin, R. Nature Immunol. 2007, 8, 913–919.
  11. Dheen, S. T.; Kaur, C.; Ling, E. A. Curr. Med. Chem. 2007, 14, 1189–1197.
  12. Drummond, D. C.; Noble, C. O.; Kirpotin, D. B.; Guo, Z.; Scott, G. K.; Benz, C. C. Ann. Rev. Pharmacol. Toxicol. 2005, 45, 495–528.
  13. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. J. Biol. Chem. 1990, 265, 17174–17179.
  14. Grant, S.; Easley, C.; Kirkpatrick, P. Nat. Rev. Drug Discovery 2007, 6, 21–22.
  15. Bieliauskas, A. V.; Pflum, M. K. Chem. Soc. Rev. 2008, 37, 1402–1413.
  16. Dayangac-Erden, D.; Bora, G.; Ayhan, P.; Kocaefe, C.; Dalkara, S.; Yelekci, K.; Demir, A. S.; Erdem-Yurter, H. Chem. Biol. Drug Des. 2009, 73, 355–364.
  17. Zeiller, J. J.; Dumas, H.; Guyard-Dangremont, V.; Berard, I.; Contard, F.; Guerrirer, D.; Ferrand, G.; Bonhomme, Y. Patent WO/2005/014521, 2005.
  18. Katritzkyi, A. R.; Feng, D.; Qi, M. J. Org. Chem. 1998, 63, 1473–1477.
  19. Stecher, E. D.; Ryder, H. F. J. Am. Chem. Soc. 1952, 74, 4392–4395.
  20. Audrain, H.; Thorhauge, J.; Hazell, R. G.; Jİrgensen, K. A. J. Org. Chem. 2000, 65, 4487–4497.
  21. Wu, Y. C.; Liu, L.; Li, H. J.; Wang, D.; Chen, Y. J. J. Org. Chem. 2006, 71, 6592–6596.
  22. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. J. Comput. Chem. 1998, 19, 1639–1662.
  23. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S.; Weiner, P. J. Am. Chem. Soc. 1984, 106, 765–784.
  24. Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. J. Comput. Chem. 1986, 7, 230–252.
  25. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. J. Comput. Chem. 2007, 28, 1145–1152. Akdo˘ gan, E. D.; Erman, B.; Yelek¸ ci, K. Turk. J. Chem. 2011, 35, 523–542.